<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To understand signaling pathways that shape inflamed tissue and predispose to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is critical for effective prevention and therapy of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have explored PI3K activity in human <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBD) and mouse <z:hpo ids='HP_0002583'>colitis</z:hpo> models </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: We performed immunostaining of phosphorylated AKT (pAKT) and unbiased high throughput image acquisition and quantitative analysis of samples of non-inflamed <z:mpath ids='MPATH_458'>normal</z:mpath> colon, <z:hpo ids='HP_0002583'>colitis</z:hpo>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Mechanistic insights were gained from ex vivo studies of cell interactions, the <z:chebi fb="0" ids="8249">Piroxicam</z:chebi> / IL-10-/- mouse model of progressive <z:hpo ids='HP_0002583'>colitis</z:hpo>, and use of the PI3K inhibitor LY294002 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Progressive increase in densities of pAKT-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated macrophages (TAMs) and increase in densities of mast cells (MCs) in the colonic submucosa were noted with <z:hpo ids='HP_0002583'>colitis</z:hpo> and progression to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>MCs recruited macrophages in ex vivo migration assays, and both MCs and TAMs promoted invasion of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Pre-treatment of MCs with LY294002 blocked recruitment of TAMs </plain></SENT>
<SENT sid="7" pm="."><plain>LY294002 inhibited MC and TAM-mediated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion, and in mice, blocked stromal PI3K, <z:hpo ids='HP_0002583'>colitis</z:hpo>, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The PI3K / AKT pathway is active in cells infiltrating inflamed human colon tissue </plain></SENT>
<SENT sid="9" pm="."><plain>This pathway sustains the recruitment of inflammatory cells through a positive feed back loop </plain></SENT>
<SENT sid="10" pm="."><plain>The PI3K / AKT pathway is essential for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion and the malignant features of the <z:chebi fb="0" ids="8249">Piroxicam</z:chebi> / IL-10-/- mouse model </plain></SENT>
<SENT sid="11" pm="."><plain>LY294002 targets the PI3K pathway and hinders progressive <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>These findings indicate that <z:hpo ids='HP_0002583'>colitis</z:hpo> and progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are dependent on stromal PI3K and sensitive to treatment with LY294002 </plain></SENT>
</text></document>